Vice President of Advancement
The Max Foundation
Posted
May 19, 2026
Location
Remote (US)
Type
Full-time
Compensation
$200000 - $250000
Mission
What you will drive
- Lead the organization's comprehensive advancement strategy, encompassing fundraising, strategic partnerships, and revenue-generating collaborations to sustain and expand The Max Foundation's mission.
- Provide executive leadership and strategic direction for all advancement functions, including fundraising and strategic partnerships.
- Design and implement a diversified advancement strategy to expand, broaden, and sustain revenue from individuals, corporations, foundations, and other institutional partners.
- Oversee donor cultivation, solicitation, and stewardship strategies to build long-term, values-aligned relationships.
Impact
The difference you'll make
This role directly accelerates health equity by securing the resources needed to bring life-extending treatments and patient-centered health care to people living with cancer and critical illness in low- and middle-income countries.
Profile
What makes you a great fit
- Master's degree in a related field required.
- 15+ years of progressive leadership experience in development, advancement, business development, or partnership-driven roles, preferably within global health or other mission-driven international development organizations.
- Demonstrated success in building and executing diversified revenue strategies at scale, including individual, corporate, and institutional funding.
- Proven ability to cultivate and manage senior-level external relationships and partnerships, including engagement with executive leaders and boards.
Benefits
What's in it for you
Salary: Not specified. Benefits: Not detailed in posting. The role offers the opportunity to lead advancement for a global health nonprofit with a mission-driven culture.
About
Inside The Max Foundation
The Max Foundation is a leading global health nonprofit dedicated to accelerating health equity, pioneering practical solutions to bring life-extending treatments to over 100,000 people in low- and middle-income countries for more than 28 years.